Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX-212C in Advanced Solid Tumors
NCT07556653Phase 1Recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Jun 2026
- Primary completion
- Apr 2027
- Modality
- Tissue Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WTX-212C in solid tumor, sponsored by Zhejiang Provincial People's Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days and Incidence and Severity of Treatment-Related Adverse Events at 12 months. Started Jun 2026; status: recruiting.
02
Drugs
WTX-212C
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07556653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556653.